Country: Israel
Language: English
Source: Ministry of Health
THIOTEPA
MBI PHARMA LTD., ISRAEL
L01AC01
POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
THIOTEPA 15 MG
I.V
Required
RIEMSER PHARMA GMBH, GERMANY
THIOTEPA
TEPADINA is indicated, in combination with other chemotherapy medicinal products:1. with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;2. when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
2015-07-28
.תשפיחש המ תא ונאצמ אל הנוכנ תנזהש תבותכה םא קודבל יאדכ תבותכב עייסל חמשנ info@gov.il ( 1 ) Read the complete document
1 SUMMARY OF PRODUCT CHARACTERISTICS _ _ 1. NAME OF THE MEDICINAL PRODUCT TEPADINA 15 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial of powder contains 15 mg thiotepa. After reconstitution with 1.5 ml of water for injections, each ml of solution contains 10 mg thiotepa (10 mg/ml). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. White crystalline powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS TEPADINA is indicated, in combination with other chemotherapy medicinal products: 1. with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; 2. when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION TEPADINA administration must be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation. Posology TEPADINA is administered at different doses, in combination with other chemotherapeutic medicinal products, in patients with haematological diseases or solid tumours prior to HPCT. TEPADINA posology is reported, in adult and paediatric patients, according to the type of HPCT (autologous or allogeneic) and disease. 2 _Adults_ _AUTOLOGOUS HPCT _ _Haematological diseases _ _ _ The recommended dose in haematological diseases ranges from 125 mg/m 2 /day (3.38 mg/kg/day) to 300 mg/m 2 /day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m 2 (24.32 mg/kg), during the time of the entire conditioning treatment. _ _ LYMPHOMA The recommended dose ranges from 125 Read the complete document